36
Participants
Start Date
November 9, 2021
Primary Completion Date
April 25, 2024
Study Completion Date
April 25, 2024
Magrolimab
Administered IV
Daratumumab
Administered either SC or IV
Pomalidomide
Administered orally
Dexamethasone
Administered orally
Bortezomib
Administered either SC or IV
Carfilzomib
Administered IV
Memorial Sloan Kettering Cancer Center - Main Campus, New York
Roswell Park Cancer Institute, Buffalo
US Oncology, Inc., IRB, Fairfax
Duke University, Durham
Levine Cancer Institute, Charlotte
The Ohio State University, Columbus
Cleveland Clinic - Taussig Cancer Institute, Cleveland
Karmanos Cancer Institute, Detroit
Hightower Clinical, Oklahoma City
US Oncology, Inc. IRB, Dallas
Huntsman Cancer Institute, Salt Lake City
Arizona Oncology Associates , PC - HOPE, Tucson
US San Diego Moores Cancer Center, La Jolla
Stanford Cancer Institute, Palo Alto
Oregon Health and Science University, Portland
Bend Memorial Clinic, P.C. d/b/a Summit Health, Bend
Cross Cancer Institute, Edmonton
Princess Margaret Cancer Centre, Toronto
Fakultní nemocnice Brno, Brno
Fakultní Nemocnice Olomouc, Olomouc
Vseobecna fakultni nemocnice v Praze, Prague
Fakultní nemocnice Ostrava, Severomoravsky KRAJ
Lead Sponsor
Gilead Sciences
INDUSTRY